The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Results from the ALLG BM12 CAST trial: PTCy for GvHD prophylaxis in matched sibling donor transplant
In this presentation, David Curtis, MBBS, FRCPA, FRCP, PhD, Monash University & Alfred Hospital, Melbourne, Australia, discusses the Phase III ALLG BM12 CAST trial (ACTRN12618000505202), which investigated the use of post-transplant cyclophosphamide (PTCy) to prevent graft-versus-host disease (GvHD) in patients receiving a matched sibling donor transplant. He highlights that the combination of cyclosporine and cyclophosphamide tripled the number of patients alive without disease and free from significant GvHD at three years, without increasing toxicities or cancer recurrence. This press briefing took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
